Piramal Pharma rises after USA facility clears USFDA inspection

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

Monday, May 13, 2024 2:26:00 PM

Asian Paints

2878.10

(3.80%)

Axis Bank

1127.40

(0.67%)

Bajaj Finance

6721.95

(0.55%)

Bajaj Finserv

1581.85

(0.55%)

Bharti Airtel

1288.05

(-1.12%)

HCL Technologi..

1314.70

(-0.12%)

HDFC Bank

1454.75

(1.19%)

Hind. Unilever

2359.40

(0.10%)

ICICI Bank

1126.95

(0.92%)

IndusInd Bank

1401.25

(-0.59%)

Infosys

1419.40

(-0.40%)

ITC

432.90

(-0.07%)

JSW Steel

857.70

(0.46%)

Kotak Mah. Ban..

1628.35

(-0.13%)

Larsen & Toubr..

3299.95

(0.87%)

M & M

2171.50

(-0.97%)

Maruti Suzuki

12610.00

(-0.52%)

Nestle India

2516.35

(-0.65%)

NTPC

352.80

(-0.82%)

Power Grid Cor..

306.10

(0.72%)

Reliance Indus..

2803.65

(-0.41%)

St Bk of India

811.30

(-0.86%)

Sun Pharma.Ind..

1520.90

(0.97%)

Tata Motors

959.55

(-8.34%)

Tata Steel

163.25

(0.55%)

TCS

3936.55

(1.04%)

Tech Mahindra

1258.00

(-0.56%)

Titan Company

3259.60

(-0.96%)

UltraTech Cem.

9557.00

(0.65%)

Wipro

450.00

(-0.38%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Piramal Pharma rises after USA facility clears USFDA inspection	Share Back
(18 Apr 2024)
Earlier in February 2024, the US Food and Drug Administration (USFDA) conducted a pre-approval inspection (PAI) inspection of the company’s Riverview (USA) facility from 29th January 2024 to 6th February 2024. On conclusion of the inspection, a Form-483 was issued with 3 observations. The observations were classified under VAI (Voluntary Action Indicated). Piramal Pharma is a pharmaceutical company that manufactures and develops a wide range of pharmaceutical solutions to reduce diseases. Piramal Pharma serves customers worldwide. The pharmaceutical company reported a consolidated net profit of Rs 10.11 crore in Q3 FY24 as compared with net loss of Rs 90.18 crore recorded in Q3 FY23. Revenue from operations rose by 14.1% year-on-year to Rs 1,958.57 crore in Q3 FY24.
Top